Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate With Method Of Treatment Patent For ZTALMY Titration Regimens

Benzinga · 10/15 20:01

New U.S. patent issued for ZTALMY® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September 2042

Marinus continues to grow its IP portfolio to protect its scientific innovation

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis complex (TSC) and Lennox-Gastaut syndrome (LGS). The U.S. patent No. 12,115,169 expires in September 2042.